SUTRO BIOPHARMA INC. - COMMON STOCK

1,1000

02-мая-25 16:45:00

15 мин. задержка

Акции

+0,0300

+2,80%

Сегодняшний диапазон

1,0300 - 1,1100

ISIN

N/A

Источник

NASDAQ

Sutro Biopharma to Participate in Upcoming Investor Conferences

01 май 2025 16:05:00 Источник Nasdaq GlobeNewswire
Sutro Biopharma to Highlight its Next-Generation Exatecan and Dual-Payload ADC Programs in Presentations at AACR 2025

28 апр 2025 16:05:00 Источник Nasdaq GlobeNewswire
Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025

15 мар 2025 18:40:00 Источник Nasdaq GlobeNewswire
Sutro Biopharma Reports Full Year 2024 Financial Results and Business Highlights

13 мар 2025 16:07:00 Источник Nasdaq GlobeNewswire
Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline

13 мар 2025 16:05:00 Источник Nasdaq GlobeNewswire
Sutro Biopharma to Present at the TD Cowen 45th Annual Health Care Conference

03 мар 2025 16:05:00 Источник Nasdaq GlobeNewswire
Sutro Biopharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference

07 янв 2025 16:05:03 Источник Nasdaq GlobeNewswire
Sutro Biopharma and Boehringer Ingelheim BioXcellence™ collaboration: Established first-in-class cell-free capabilities at commercial scale

07 янв 2025 09:00:00 Источник Nasdaq GlobeNewswire
Sutro Biopharma Announces Selected Dose for Luvelta and Topline Results from Dose-Optimization Portion of REFRαME-O1 Trial in Platinum Resistant Ovarian Cancer

10 дек 2024 08:00:00 Источник Nasdaq GlobeNewswire
Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights

13 ноя 2024 16:30:00 Источник Nasdaq GlobeNewswire
Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference

04 ноя 2024 16:05:00 Источник Nasdaq GlobeNewswire
Sutro Biopharma Announces Initiation of the Registration-enabling REFRαME-P1 Trial with Luvelta for Pediatric Patients with CBF/GLIS AML

01 ноя 2024 08:00:00 Источник Nasdaq GlobeNewswire
Sutro Biopharma Highlights Next-Generation ADC Innovation and Near-term Pipeline at Research Forum

10 окт 2024 16:05:00 Источник Nasdaq GlobeNewswire
Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

20 сен 2024 16:01:00 Источник Nasdaq GlobeNewswire
Sutro Biopharma Announces Updated Data from Phase 1b Study of Luvelta in Combination with Bevacizumab at ESMO 2024

14 сен 2024 03:00:00 Источник Nasdaq GlobeNewswire
Sutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pipeline, on October 10, 2024

11 сен 2024 08:00:00 Источник Nasdaq GlobeNewswire
Sutro Biopharma Announces Initiation of REFRαME-L1 Phase 2 Trial with Luvelta for Patients with Non-Small Cell Lung Cancer

22 авг 2024 08:00:00 Источник Nasdaq GlobeNewswire
Sutro Biopharma Reports Second Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones

13 авг 2024 16:30:00 Источник Nasdaq GlobeNewswire
Sutro Biopharma Appoints Dr. Barbara Leyman as Chief Business Development Officer

09 июл 2024 08:00:00 Источник Nasdaq GlobeNewswire
Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones

13 май 2024 16:30:00 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.